The objective of this retrospective chart review is to evaluate drug utilization, usage patterns and indication of effectiveness Eylea in the routine clinical (real-life) management of patients who suffer from ME (Macular Edema), secondary to CRVO (Central Retinal Vein Occlusion), and who started treatment with Eylea for this indication.
Study Type
OBSERVATIONAL
Enrollment
126
Eylea (intravitreal aflibercept) is an anti-Vascular Endothelial Growth Factor (VEGF) drug indicated for neovascular age-related macular degeneration (AMD), visual impairment due to diabetic macular edema (DME) and visual impairment due to macular edema (ME) secondary to central or branched retinal vein occlusion (RVO). RVO, both branch and central, is the second most common type of retinal vascular disorders after diabetic retinal disease. Central retinal vein occlusion (CRVO) is characterized by an obstruction of the central retinal vein combined with variable amounts of retinal arterial insufficiency.
Unnamed facility
Multiple Locations, Belgium
Treatment duration
Time frame: At 12 months of treatment with Eylea
Number of eyes treated (mono-and biocular)
Time frame: At 12 months of treatment with Eylea
Change in visual acuity (BCVA score)
Time frame: At 12 months of treatment with Eylea
Number of Eylea injections per treated eye
Time frame: At 12 months of treatment with Eylea
Estimation of percentage (%) of eyes which need additional treatment after 2 years at the discretion of the treating physician.
Time frame: At 12 months of treatment with Eylea
Sufficiency of reimbursed number of Eylea injections (max. 9 injections/eye in year 1) for treatment of all patients during the first year of treatment.
Time frame: At 12 months of treatment with Eylea
Number of patients who discontinued their treatment with Eylea prematurely
Investigator is asked to categorize the number of patients who ended their treatment prematurely according to the following reasons : * Lost-to-follow up (measured as number of patients) * Lack of efficacy (measured as number of patients) * Remission (measured as number of patients) * AE (measured as number of patients) * Other (measured as number of patients)
Time frame: At 12 months of treatment with Eylea
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.